About: http://data.cimple.eu/news-article/9196388a744019f69720bd04b209cb5540586205d46772619192150a

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/9196388a744019f69720bd04b209cb5540586205d46772619192150a Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	French pharmaceutical giant Sanofi and Britain's GSK announced Thursday the start of final tests of their belated Covid vaccine as they race to add their jab to the world's arsenal against the pandemic. The companies reported positive results from interim human trials earlier this month after a disappointing outcome from initial studies last year left France without its own vaccine, denting national pride. Sanofi and GlaxoSmithKline on Thursday started enrolment for Phase 3 of a clinical study that will include more than 35,000 adult volunteers at sites in the United States, Asia, Africa and Latin America, the firms said. The companies hope to launch their vaccine by the end of 2021 -- one year after Pfizer and Moderna jabs were approved by regulators. The Phase 3 trial will initially investigate the vaccine's efficacy against the original coronavirus that was first detected in Wuhan, China and then look at its response to a variant found in South Africa. Sanofi and GSK will also study their vaccine's ability to work as a booster shot in people who had previously received another vaccine. The Phase 2 trials already showed a strong immune response after a single shot in participants who had previously contracted the coronavirus. "We have adapted our vaccine development strategy based on forward-looking considerations as the virus continues to evolve, as well as anticipating what may be needed in a post-pandemic setting," Sanofi executive vice president Thomas Triomphe said in a statement. Like most of the other jabs in circulation, the Sanofi-GSK vaccine would require two doses. The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine. jdy/ak/lth/wdb
schema:headline	Sanofi, GSK launch final phase of Covid vaccine trials
schema:mentions	Latin America Antigen Booster dose Pharmaceutical industry Clarence Thomas French language GlaxoSmithKline Asia Jab Africa Wuhan South Africa Pandemic France Virus Pfizer Coronavirus disease Vaccine United States China Severe acute respiratory syndrome coronavirus 2 AK-74 Adjuvant Ouvrage Denting Immunogenicity Monoclonal antibody Sanofi
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-05-27 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	90 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software